Ciprofloxacin Ophthalmic Solution, USP 0.3%

/Ciprofloxacin Ophthalmic Solution, USP 0.3%
Ciprofloxacin Ophthalmic Solution, USP 0.3%2018-09-06T09:12:40+00:00

Prescription Drug Name:

Ciprofloxacin Ophthalmic Solution, USP 0.3%

ID:

818ac933-6d45-4b7a-9a6e-3f671646f132

Code:

34391-3

DESCRIPTION


id: 4899744a-afad-4b16-91ca-cc7285546fbc
displayName: DESCRIPTION SECTION
FDA Article Code: 34089-3

Ciprofloxacin Ophthalmic Solution, USP is a synthetic, sterile, multiple dose, antimicrobial for topical ophthalmic use. Ciprofloxacin is a fluoroquinolone antibacterial active against a broad spectrum of gram-positive and gram-negative ocular pathogens. It is available as the monohydrochloride monohydrate salt of 1-cyclopropyl-6-fluoro-1,4-dihydro-4- oxo-7-(1-piperazinyl)-3-quinoline-carboxylic acid. It is a faint to light yellow crystalline powder with a molecular weight of 385.8. Its empirical formula is C17H18FN3O3•HCl•H2O and its chemical structure is as follows: Ciprofloxacin differs from other quinolones in that it has a fluorine atom at the 6-position, a piperazine moiety at the 7-position, and a cyclopropyl ring at the 1-position. Each mL of Ciprofloxacin Ophthalmic Solution, USP contains: Active: Ciprofloxacin HCl, USP 3.5 mg equivalent to 3 mg base. Preservative: Benzalkonium Chloride 0.006%. Inactives: Acetic Acid, Edetate Disodium 0.05%, Mannitol 4.6%, Sodium Acetate, Hydrochloric Acid and/or Sodium Hydroxide (to adjust pH) and Water for Injection. The pH is approximately 4.5 and the osmolality is approximately 300 mOsm.

INDICATIONS AND USAGE


id: 33eb849d-fbd5-4c5e-8e1f-e2c840764367
displayName: INDICATIONS & USAGE SECTION
FDA Article Code: 34067-9

Ciprofloxacin Ophthalmic Solution is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below:

Corneal Ulcers: Pseudomonas aeruginosa
Serratia marcescens*
Staphylococcus aureus
Staphylococcus epidermidis
Streptococcus pneumoniae
Streptococcus (Viridans Group)*
Conjunctivitis: Haemophilus influenzae
Staphylococcus aureus
Staphylococcus epidermidis
Streptococcus pneumoniae
*Efficacy for this organism was studied in fewer than 10 infections.

CONTRAINDICATIONS


id: 76c4321a-3dcd-4276-aae6-780635610f16
displayName: CONTRAINDICATIONS SECTION
FDA Article Code: 34070-3

A history of hypersensitivity to ciprofloxacin or any other component of the medication is a contraindication to its use. A history of hypersensitivity to other quinolones may also contraindicate the use of ciprofloxacin.

WARNINGS


id: 540d1726-8b4e-4d62-912e-e3dd7462bebb
displayName: WARNINGS SECTION
FDA Article Code: 34071-1

NOT FOR INJECTION INTO THE EYE. Serious and occasionally fatal hypersensitivity (anaphylactic) reactions, some following the first dose, have been reported in patients receiving systemic quinolone therapy. Some reactions were accompanied by cardiovascular collapse, loss of consciousness, tingling, pharyngeal or facial edema, dyspnea, urticaria, and itching. Only a few patients had a history of hypersensitivity reactions. Serious anaphylactic reactions require immediate emergency treatment with epinephrine and other resuscitation measures, including oxygen, intravenous fluids, intravenous antihistamines, corticosteroids, pressor amines and airway management, as clinically indicated. Remove contact lenses before using.

ADVERSE REACTIONS


id: 93cceb50-a652-4005-9c23-5ec0aa57ffab
displayName: ADVERSE REACTIONS SECTION
FDA Article Code: 34084-4

The most frequently reported drug related adverse reaction was local burning or discomfort. In corneal ulcer studies with frequent administration of the drug, white crystalline precipitates were seen in approximately 17% of patients (see PRECAUTIONS ). Other reactions occurring in less than 10% of patients included lid margin crusting, crystals/scales, foreign body sensation, itching, conjunctival hyperemia and a bad taste following instillation. Additional events occurring in less than 1% of patients included corneal staining, keratopathy/keratitis, allergic reactions, lid edema, tearing, photophobia, corneal infiltrates, nausea and decreased vision.

OVERDOSAGE


id: 81b8c6ea-4151-48bf-bc6c-1f7bd86bae7d
displayName: OVERDOSAGE SECTION
FDA Article Code: 34088-5

A topical overdose of Ciprofloxacin Ophthalmic Solution may be flushed from the eye(s) with warm tap water.

HOW SUPPLIED


id: 69658dd2-7b39-4eda-910a-b2ad55a3c435
displayName: HOW SUPPLIED SECTION
FDA Article Code: 34069-5

Product: 50090-3184 NDC: 50090-3184-0 2.5 mL in a BOTTLE, DROPPER / 1 in a CARTON

ANIMAL PHARMACOLOGY


id: 864388b2-b941-44d4-8be5-33bdc853d427
displayName: ANIMAL PHARMACOLOGY & OR TOXICOLOGY SECTION
FDA Article Code: 34091-9

Ciprofloxacin and related drugs have been shown to cause arthropathy in immature animals of most species tested following oral administration. However, a one-month topical ocular study using immature Beagle dogs did not demonstrate any articular lesions. AKORN
Manufactured by: Akorn, Inc.
Lake Forest, IL 60045
CX00N           Rev. 04/17

Ciprofloxacin Hydrochloride


id: 47bd247a-553f-4165-91b2-fe6835b06475
displayName: PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
FDA Article Code: 51945-4